Anti-glomerular basement membrane disease after alemtuzumab.
Clatworthy
Menna R
MR
Wallin
Elizabeth F
EF
Jayne
David R
DR
D058186:Acute Kidney Injury / Q000139:chemically induced; D000328:Adult; D000074323:Alemtuzumab; D019867:Anti-Glomerular Basement Membrane Disease / Q000139:chemically induced*; D019268:Antibodies, Antineutrophil Cytoplasmic; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008297:Male; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy; D014657:Vasculitis / Q000188:drug therapy / Q000276:immunology
D019268:Antibodies, Antineutrophil Cytoplasmic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D000074323:Alemtuzumab